Live Salesforce, Inc. Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow MIRA PHARMACEUTICALS, INC.

Get SEC filing alerts via email and in your feed for MIRA PHARMACEUTICALS, INC.

MIRA

MIRA PHARMACEUTICALS, INC.

About MIRA PHARMACEUTICALS, INC.

MIRA Pharmaceuticals Inc. is a clinical-stage biotech focused on developing novel neuroscience therapies. Its key products include Ketamir-2, an oral ketamine analog for neuropathic pain and depression, and MIRA-55, a cannabinoid-based compound targeting neuroinflammation and cognitive decline. The company operates in North America, emphasizing safety, efficacy, and regulatory compliance to address unmet medical needs in neuropsychiatric and neurological disorders.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from MIRA PHARMACEUTICALS, INC.

1
1
MIRA PHARMACEUTICALS, INC. Mira Pharmaceuticals Reports Q1 2026 Financial Results with $1.15 Million Net Loss

Via official filing (AI summary) | 21 days ago | 0 comments

2
1
MIRA PHARMACEUTICALS, INC. MIRA Pharmaceuticals Reports $10.4 Million Net Loss and Acquires SKNY Pharmaceuticals

Via official filing (AI summary) | 2 months ago | 0 comments

3
1
MIRA PHARMACEUTICALS, INC. Mira Pharmaceuticals Reports Significant Asset Growth and Ongoing Losses in Q3 2025

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
MIRA PHARMACEUTICALS, INC. Mira Pharmaceuticals Reports $1.54 Million Net Loss in Q2 2025, Pursues Acquisition of SKNY Pharmaceuticals

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
MIRA PHARMACEUTICALS, INC. Mira Pharmaceuticals Reports $1.8 Million Net Loss in Q1 2025, Plans Acquisition of SKNY Pharmaceuticals

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
MIRA PHARMACEUTICALS, INC. MIRA Pharmaceuticals Reports $7.9 Million Net Loss, Advances Key Drug Candidates

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
MIRA PHARMACEUTICALS, INC. Mira Pharmaceuticals Reports Financial Changes, Net Loss Improvement, and Focus on Lead Compounds

Via official filing (AI summary) | over 1 year ago | 0 comments